Please assess the completion status of the following clinical trial:

Trial Title: UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects chronically infected with HCV genotype 1~* HCV RNA ≥ 10,000 IU/mL at screening~* Treatment-naïve subjects with no previous exposure to an interferon formulation (ie, IFNα, pegIFNα), RBV, or HCV DAA (protease, polymerase inhibitor, etc.)~* Treatment-experienced subjects are eligible~Exclusion Criteria:~* Evidence of cirrhosis~* Liver or any other organ transplant~* Current or known history of cancer within 5 years prior to enrollment~* Documented or suspected HCC~* Evidence of decompensated liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A 1: DCV/ASV/BMS-791325 in treatment-naive subjects (Type: EXPERIMENTAL): Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
- A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects (Type: EXPERIMENTAL): Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).